Background: With recent advances in the management of chronic liver disease and its complications, the long-term survival in cirrhosis has improved. Therefore, the number of individuals who will spend a significant proportion of their life with endstage liver disease (ESLD) may continue to rise. Thus, more attention to quality of life (QOL) and its integration with traditional clinical endpoints is needed.
| INTRODUCTION
Over the past decade hepatitis C, alcohol related cirrhosis and nonalcoholic steatohepatitis have been the most common causes for end-stage liver disease, accounting for 80% of individuals waiting for a liver transplant (LT) in the USA. 1 With the advent of direct acting anti-virals, the requirement for LT will decline in patients with hepatitis C cirrhosis. Furthermore, many patients with non-alcoholic steatohepatitis cirrhosis are diagnosed at a later age and their comorbidities may preclude them as candidates for LT. 1 Thus, many individuals may live a significant proportion of their life with cirrhosis.
The rising number of individuals who will spend a significant proportion of their life with end-stage liver disease (ESLD) should lead us to focus our attention on quality of life (QOL). QOL is a broad concept reflecting the overall health status of the individual filtered by his or her perceptions. The perceptions include the measurable concepts of QOL such as mental well-being, physical health, functional status, social relationships, personal beliefs' and overall
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health status. 2, 3 The complications related to cirrhosis such as hepatic encephalopathy (HE) and ascites, have been shown to influence patient sense of well-being and life satisfaction. 4, 5 Moreover, patients with chronic liver disease and cirrhosis have been shown to have a lower QOL when compared to the general population. 6, 7 This is especially important in those approaching the end-of-life. Studies have shown patients with ESLD approaching the end-of-life experience more suffering in comparison to those dying of other chronic disease. 8 Over the last few years, there have been several studies looking specifically at treatment outcomes and their impact on the QOL in patients with ESLD. The aim of this review was to summarise and compare the insights gained from these intervention studies and to make concise recommendations to further promote and improve QOL in this patient population.
| ME TH ODS
A literature search was conducted using PubMed and Web of 
| Nutritional therapy
Malnutrition is a common complication seen in patients with cirrhosis; it has been reported in 50%-90% of patients. 9, 10 The wide range reported is likely due to different definitions used for fat and protein malnutrition, defined as reduction in body fat mass and sarcopenia, respectively, 11, 12 as well as the varying degree of liver dysfunction or failure. Factors that contribute to malnutrition in chronic liver disease include inadequate oral intake, due to early satiety in moderate to severe ascites, or to sodium restriction decreasing food palatability, in the setting of an increasingly catabolic state as liver function deteriorates. Other factors include metabolic abnormalities and malabsorption; a third (34%) of cirrhotic patients are considered to be hypermetabolic with a resting energy expenditure 120% of the expected value. 13, 14 The elevated pro-inflammatory and anti-inflammatory cytokine levels present in ESLD likely contribute to this hypermetabolic state. 15 Poor nutritional status has been linked with a decrease in health-related QOL (HRQOL). 16 As early recognition and management can improve patient morbidity and mortality, 10, 12 it is important to consider nutritional therapy as a key aspect in the management of liver cirrhosis.
Various metabolic changes are present in patients with liver cirrhosis. These individuals have an abnormal fuel metabolism and exhibit increased fat oxidation and decreased glucose oxidation.
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As a result, they experience early starvation after an overnight fast; in a cirrhotic, an overnight fast is comparable to a 72 h fast in a healthy individual. 10 These patients also commonly have proteinenergy malnutrition. 20 These observations have led to studies looking at the impact of nutrition therapy on QOL. For example, nutrition counselling and recommendation of late-evening snacks with branched-chain amino acids have been shown to decrease proteinenergy malnutrition and improve QOL. 21 Similarly, Yamanaka-Okumura et al. assessed the impact of nutritional supplement, taken as a late-evening snack, on HRQOL (Table 1) . 22 Nutrition counselling was provided to patients in both the late-evening snack and non-late evening snack groups; where those in the late-evening snack group had an extra 200 kcal before bedtime. The short form 36 questionnaire was used to measure HRQOL (see Table 2 ), with similar baseline scores in the two groups; these scores were lower when compared to the general population. During follow-up, there was a significant improvement in the late-evening snack group with regards to general health perceptions, role-emotional and mental health components of the short form 36.
In another study, daytime administration of branched-chain amino acids was shown to significantly improve QOL in patients with cirrhosis after 3 months of treatment. The Short Form Health Survey 8 questionnaire (see Table 2 ) was used to assess QOL. At the end of treatment, there was an improvement in general health, vitality, social function, mental health and role limitation due to emotional problems.
23.
There have also been studies looking at nutrition therapy in management of minimal hepatic encephalopathy (MHE) and its impact on QOL; as nutrition may have a role in management of MHE.
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Kato et al. evaluated improvement in MHE and QOL due to nutritional therapy. 24 They enrolled patients without a prior history of HE who met criteria for MHE. All patients received nutritional counselling and were advised to consume 30-35 kcal/kg/day and 1.0- 26 The sickness impact profile questionnaire was used to assess HRQOL 27 (see Table 2 ), with comparable baseline sickness impact profile scores in both groups. The change in sickness impact profile scores was significantly higher in the group receiving nutritional therapy in comparison to the control group. Furthermore, the change in sickness impact profile scores correlated with improved cognition, and improved nutritional parameters including mid-arm circumference, hand grip and skeletal mass. Thus, suggesting improvement in nutritional parameters was correlated with improved encephalopathy and HRQOL. There was an overall improvement in QOL in both groups during follow-up However, there were no significant differences in the scores between the two groups G€ ulberg et al. 
| Management of hepatic encephalopathy
Hepatic encephalopathy is a debilitating complication of cirrhosis leading to a decrease in HRQOL [28] [29] [30] as a result of inability to perform activities of daily living, increased dependence on care givers 31 and increased hospitalisations. 32, 33 The ability to drive is essential in performing activities of daily living and leads to increased independence. Patients with HE or MHE have been shown to have driving impairment with a high rate of motor vehicle accidents seen in those with MHE. 30 Fatigue is a common symptom present in patients with encephalopathy and further contributes to driving impairment. 34 Patients with HE, even MHE, should be counselled against driving a motor vehicle due to the increased risk for motor vehicle accidents.
This restriction no doubt further reduces HRQOL. 35 HE presents as a wide spectrum of neurological and neuropsychiatric abnormalities ranging from subclinical alterations to a coma. MHE is part of the spectrum with subclinical changes. MHE has been diagnosed by means of neuropsychometric and neuropsychological tests. [36] [37] [38] The range for prevalence of MHE has been reported anywhere from 30% to 84% 39, 40 ; this range is likely due to lack of a gold standard for the diagnosis of MHE. Nevertheless, the diagnosis of MHE is important as it prognosticates the development of overt HE. Moreover, the development of HE, whether subclinical or overt, leads to reduced survival. [41] [42] [43] Rifaximin and lactulose are both effective in the treatment of HE and have been shown to lead to favourable QOL outcomes. In a randomised clinical trial, rifaximin use for treatment of HE was associated with an improvement in HRQOL. 44 Rifaximin as opposed to lactulose was used as it was felt that the gastrointestinal side effects of lactulose led to noncompliance, 32 recurrent episodes of HE and therefore worsening HRQOL. 16, 45 Patients with a prior episode of HE were included in the study, and were randomised to either placebo, or rifaximin (with concomitant lactulose use in 93% and 95% of each arm). The Chronic Liver Disease Questionnaire was used to evaluate change in HRQOL (see Table 2 ). Overall, those enrolled in the rifaximin group had significantly higher chronic liver disease questionnaire scores, with a uniform effect across all the domains, in comparison to the placebo group. Furthermore, patients who had overt breakthrough HE had significantly lower scores when compared to those who maintained remission. This effect was seen across all aspects of their HRQOL. These results suggest an inverse relationship between breakthrough HE episodes and chronic liver disease questionnaire scores, reflecting an impairment of HRQOL.
In another trial, Prasad et al., assessed lactulose use for management of MHE and change in HRQOL. 35 Patients fulfilling criteria for MHE were randomised to receive lactulose or no treatment. The sickness impact profile questionnaire was used to assess HRQOL.
Patients with MHE had significantly worse total sickness impact profile scores, psychosocial and physical sub-scores in comparison to individuals without MHE. During follow-up, individuals on lactulose had a significantly higher change in the sickness impact profile scores. The overall improvement in HRQOL correlated with improvement in encephalopathy.
Similarly, the use of rifaximin in MHE and change in HRQOL was assessed in another study. 46 Patients with MHE were enrolled in the study and were randomised to either rifaximin or placebo. HRQOL was assessed using the sickness impact profile questionnaire. Those on Rifaximin had significantly improved total sickness impact profile score, psychosocial and physical sub-scores after treatment when compared to their counterparts. The improvement in HRQOL strongly correlated with the improvement of encephalopathy.
In an observational study, the use of L-ornithine-L-aspartate in patients with HE was assessed with regards to impact on HRQOL. 47 In this study, patients with HE received L-ornithine-L-aspartate for 8 weeks. The effects of treatment were assessed at weeks 4 and 8.
HRQOL was assessed using the chronic liver disease questionnaire.
During follow-up, 95% of patients had an improvement in chronic liver disease questionnaire scores across all domains. The most 27 The SIP is a generic tool comprised of 136 items grouped into 12 scales Scales -sleep and rest, eating, work, home management, recreation and pastimes, ambulation, mobility, body care and movement, social interaction, alertness, emotional behaviour and communication Maharshi et al. 25 Sidhu et al. 46 Prasad et al. 35 • 
| Treatment of ascites
Approximately 50% of cirrhotic patients will develop ascites, 48 one of the most common indications for hospital admission. 49 Ascites has been shown to negatively impact HRQOL 50 and is an independent predictor of poor HRQOL particularly affecting the domains of bodily pain, general and mental health in the short form 36 questionnaire. 6 The management of ascites includes a low salt diet (<2 g/day) and diuretic agents. Refractory ascites is defined as lack of response to low salt diet, high dose diuretic therapy or rapid recurrence of ascites following therapeutic paracentesis. 51 In these cases, TIPSS has been used. Randomised controlled trials have shown better control of ascites with TIPSS in comparison to large volume paracentesis. [52] [53] [54] [55] In these studies, there was a similar incidence of HE, but more severe HE in the TIPSS group. Another study specifically evaluated the effect on QOL after TIPSS in patients with refractory ascites. 57 In this study, patients with refractory ascites underwent a TIPSS procedure. QOL was measured using the Spitzer index 58 (see Table 2 ), and rated by patients using a visual analogue scale. During follow-up, the scores for QOL increased using both methods. The changes in scores were most pronounced in patients with complete response to TIPSS in comparison to nonresponders, signifying, not surprisingly, the improvement in QOL was associated with response to treatment.
Zhuang et al. also assessed QOL after TIPSS insertion, 59 where the indication for this procedure in most patients (71%) was refractory variceal bleeding. QOL was assessed using the Rand 36-Item Health Survey 1.0. 60 After the TIPSS procedure, the scores in all the categories of health status improved. There was a statistically significant improvement in the status of limitations due to emotional problems, energy and fatigue, emotional well-being, and health change.
Of note, a recent study assessing TIPSS, in patients with refractory ascites showed a decreased risk of complications related to portal hypertension and reduced hospitalisations compared to those who received large volume paracentesis. 61 There was no difference in HE in the two groups. In addition, the TIPSS group had a significantly improved transplant free survival. Similarly, prior studies have shown improved survival in select patients receiving TIPSS for variceal bleeding. 
| End-of-life care
Initiating a palliative care consult in this patient population is crucial.
Patients with decompensated cirrhosis have a reduced long-term survival, with up to half of the patients dying within 5 years. 63 Moreover, those who are removed from the LT waiting list have a mean survival of less than 2 months. 64 Patients with ESLD who have an increased risk of dying within 12 months are eligible for palliative care. 65 Palliative care identifies and addresses important components of QOL, including physical, psychosocial and spiritual aspects whereby optimising the QOL in these patients. 65 ,66 Yet, studies show palliative care is underused in this patient population with only 10%-20% of patients having the palliative care team involved in their care. 64, 67 Furthermore, half of the palliative care consults occurred within 3 days of death and 20% occurred on the same day as death.
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having moderate to severe pain. 8 These patients report pain levels similar to patients with lung and colon cancer. 8 However, pain management in this patient population creates apprehension in most physicians, due to the complex pathophysiology in liver disease and altered drug metabolism. As a result, pain management in this patient population tends to be less aggressive leading to undue suf- 
| Methodological issues on the use of patient reported outcomes
Assessment of HRQOL has an important implication for the patient, thus patient reported outcomes are increasingly used in randomised, controlled trials. The results from the patient reported outcomes are used to improve patient-centred care, in clinical decision-making, and in developing health policy. 70 Despite their importance, there continues to be methodological issues with their use in randomised controlled trials. In a review of randomised, controlled trials only about half provided a rationale for the selected patient reported outcome, and included a hypothesis regarding its use. 71 Only a quarter of these provided any information regarding missing data. 71 Another study evaluating use of patient reported outcomes in randomised, controlled trials found in larger trials patient reported outcomes were less likely to be primary outcomes. 72 In most publications, information on how the patient reported outcome was administered was missing. Again, missing data on patient reported outcomes were not uniformly reported, and how these missing data were handled was reported in less than 20% of the trials. Reasons for patient dropout leading to missing data was also infrequently reported The short form 36 is the most commonly used generic questionnaire 73 and should be selected as the tool of choice in patients with cirrhosis. It is comprised of 36 questions, split into eight subscales, four domains and two summary scores including a physical component and a mental component summary score (see Table 2 ). All scores are expressed as T scores with a score of 50 corresponding to the US mean and 10 corresponding to 1 standard deviation;
higher scores represent better QOL. Its advantages include multiple versions in foreign languages, norm-based scoring, and easy to use format making it the most widely used tool. The use of short form 36 also allows for comparison of scores with other diseases or a healthy population. It is considered to be sensitive in a wide range of individuals; those with normal health to those who have severe levels of disability. 74 Its disadvantages include the use of US norms, which may not be applicable to other populations. This instrument has not been designed to identify disease-specific domains which may be important in establishing clinical changes. 75 Its use should therefore be combined with the use of a disease-specific tool such as chronic liver disease questionnaire or the short form version of liver disease QOL.
The Chronic Liver Disease Questionnaire is the most widely used disease-specific tool in patients with ESLD. 73 It consists of 29 questions split into six domains (see Table 2 ); higher scores represent better HRQOL. Its advantages include an easy to use format and a simple scoring system. One of its limitations is the lack of sensitivity in capturing small variations in HRQOL. This tool is unable to discriminate between more advanced liver disease. 76 As a result, the short form version of liver disease QOL should be considered as it provides greater responsiveness, especially in the setting of advanced disease. 73 The short form version of liver disease QOL uses the short form 36 as a generic core and adds 36 liver-specific questions, split into 9 scales. The disadvantage of this tool is its limited use, and thus limited published data. Studies have shown shared decision-making leads to improved patient satisfaction, adherence, QOL and well-being. 78 Early involvement of palliative care is crucial in this patient population. As QOL is impacted by psychological, emotional and spiritual domains, all of which are addressed by palliative care leading to improved QOL and quality of end-of-life care. Early initiation of palliative care involvement is necessary to have a meaningful effect on these outcomes and may also prolong quantity of life. 79, 80 As a result, there needs to be an increased effort to assess the impact of palliative care intervention in this study population.
Further studies of QOL metrics in other clinical aspects of ESLD including debility and exercise, pain control and sexual dysfunction are needed.
ACKNOWLEDG EMENTS
Declaration of personal interests: None.
AUTHORSHIP
Guarantor of the article: KD Watt.
Author contributions: Rahima A. Bhanji, Elizabeth J. Carey, and
Kymberly D. Watt contributed equally to this work. All authors approved the final version of the manuscript.
R E F E R E N C E S

